Eniola's CCT model and computational neuroscience/pharmacology work is thematically well-aligned with NAD's translational neuroscience remit, and the 16-fellowship cohort model could accommodate an interdisciplinary profile. However, a critical eligibility barrier exists: NAD PhD requires a Master's degree (or equivalent) as a prerequisite, and Eniola currently holds only a B.Pharm and is not yet enrolled in an MSc — her earliest MSc start is Oct 2026 at MUG/Graz. This is a hard stage mismatch; she should revisit this programme in 2027–2028 once the MSc is underway or completed.